Cyclobenzaprine 5.6mg Daily Transmucosal Fibromyalgia Treatment Patent
Summary
USPTO published application US20260108477A1, filed December 16, 2025 (Application No. 19421039), discloses methods for treating fibromyalgia using 5.6mg cyclobenzaprine HCl daily via transmucosal administration in a eutectic form with a basifying agent. The application names Seth Lederman and Gregory M. Sullivan as inventors. CPC classifications include A61K 31/135 (quinoline/dihydroquinoline compounds) and A61P 25/00 (nervous system disorders).
“Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and/or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published application US20260108477A1 disclosing a method of treating fibromyalgia and associated symptoms of pain, sleep disturbance, and fatigue by administering 5.6mg cyclobenzaprine HCl per day via transmucosal route in a eutectic form with a basifying agent.
Affected parties include pharmaceutical developers, drug formulation companies, and researchers studying fibromyalgia treatments; the application may inform R&D strategies for novel drug delivery formulations targeting neurological conditions.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA
Application US20260108477A1 Kind: A1 Apr 23, 2026
Inventors
Seth Lederman, Gregory M. Sullivan
Abstract
Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and/or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.
CPC Classifications
A61K 31/135 A61K 9/006 A61P 25/00
Filing Date
2025-12-16
Application No.
19421039
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.